Sobi to relocate its global headquarters in Stockholm, Sweden
We are pleased to announce the relocation of our global headquarters to the Fenix Sthlm building in Hagastaden, Stockholm, Sweden. With this move, we will continue to be in an international environment with leading experts in healthcare, as well as research and development. In addition, with proximity to the country’s largest hospital and other stakeholders in life science.
The new office will feature a modern and open layout, providing our employees with a collaborative workspace and premises suitable for our current and future business.
“The relocation of our headquarters marks the next step in Sobi’s growth journey. We are confident that the new office will help us to continue to serve people living with rare diseases and our customers in the best way possible while also providing our employees with an environment conducive to innovation and growth,” says Christine Wesström, Head of Global Technical Operations and responsible for Facilities Sweden at Sobi.
The move is planned for quarter 3, 2024.
JLL has acted as advisor to Sobi.
We provide access to innovative treatments that transform life for people.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Every day, we work actively to find better ways to understand and meet patient needs.
Find out more about our business and financial performance.
Here we present current and past media releases, images and videos.
- About
- Therapeutic areas
- Medicines
- Stories
- Sustainability
- Careers
- Investors
- Media
- English
- Swedish